This study is conducted in the United States of America (USA). The aim of this study is to investigate the at-home-administration of bypassing agents for treatment of bleeding episodes in patients with congenital haemophilia with inhibitors to factors VIII and IX. We are further investigating how bleeding episodes affect the quality of life of the patient and their family or caregivers.
Study Type
OBSERVATIONAL
Enrollment
52
This is an observation of how patients/caregivers dose bypassing agents at home for haemophilia with inhibitors
This is an observation of how patients/caregivers dose bypassing agents at home for hemophilia with inhibitors
Novo Nordisk Investigational Site
Plainsboro, New Jersey, United States
Characterisation of dose and dosing intervals for each bleeding episode
Time frame: after 3-6 months
Effect of type of bleed on initial dose, dosing interval and total dose
Time frame: after 3-6 months
Effect of initial dose and dosing interval on total dose, time to first perceived improvement, time to perceived bleed resolution
Time frame: after 3-6 months
Effect of time to first dose on dosing interval and total dose
Time frame: after 3-6 months
Effect of bleeds and drug administration time on planned daily activities
Time frame: after 3-6 months
Relationship of dose and dosing intervals to reported SAEs
Time frame: after 3-6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.